Tresiba and Lantus are both long-acting insulins used to manage blood sugar levels in people with type 1 or type 2 diabetes. (For more information on each’s drug uses, see the “What are Tresiba and ...
Tresiba (insulin degludec) is a brand-name drug that’s prescribed for diabetes. The medication is available as a liquid vial and a prefilled injection pen. The cost of Tresiba with and without ...
Bagsværd, Denmark, 21 January 2013 – Novo Nordisk today announced that the European Commission has granted marketing authorisations for Tresiba® (insulin degludec) and Ryzodeg® (insulin ...
Bagsværd, Denmark, 23 February 2016 - Novo Nordisk today announced the headline results from SWITCH 1, the second of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, ...
People with diabetes have been hit with a five-month shortage of a vital medication. The Tresiba FlexTouch U100 insulin pen, which is manufactured by global pharmaceutical giant Novo Nordisk, is ...
ESOMAR-certified consulting firm Future Market Insights (FMI) projects the global smart insulin pens market is likely to surpass the billion dollar mark by 2021, expanding at a positive CAGR, as per a ...
New generation insulin sales for Novo (NVO) came in a 1.4 billion kroner for fiscal 2015, up by 118.5%. This figure includes sale of Tresiba, Xultophy, and Ryzodeg. Novo launched Tresiba in the US in ...
ESOMAR-certified consulting firm Future Market Insights (FMI) projects the global smart insulin pens market is likely to surpass the billion dollar mark by 2021, expanding at a positive CAGR, as per a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback